Resultados de un programa de detección precoz de la hipoacusia neonatal

Barreiro, Silvia A. Borkoski; González, J. Segura; Yanes, Jorge Bueno; Bermúdez, José L. Pérez; Cano, Zoraida López; Macías, Ángel Ramos

doi:10.1016/j.otorri.2012.07.004

Cited by 12 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several international studies have reached index of coverage greater than or equal to 95% and were the ones who conducted the hearing screening especially before hospital discharge [9–12]. Brazilian studies showed coverage rates between 69% and 90% [13, 14].…”

Section: Discussionmentioning

confidence: 99%

Newborn Hearing Screening and Early Diagnostic in the NICU

Colella-Santos

Hein

Souza

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

The aim was to describe the outcome of neonatal hearing screening (NHS) and audiological diagnosis in neonates in the NICU. The sample was divided into Group I: neonates who underwent NHS in one step and Group II: neonates who underwent a test and retest NHS. NHS procedure was automated auditory brainstem response. NHS was performed in 82.1% of surviving neonates. For GI, referral rate was 18.6% and false-positive was 62.2% (normal hearing in the diagnostic stage). In GII, with retest, referral rate dropped to 4.1% and false-positive to 12.5%. Sensorineural hearing loss was found in 13.2% of infants and conductive in 26.4% of cases. There was one case of auditory neuropathy spectrum (1.9%). Dropout rate in whole process was 21.7% for GI and 24.03% for GII. We concluded that it was not possible to perform universal NHS in the studied sample or, in many cases, to apply it within the first month of life. Retest reduced failure and false-positive rate and did not increase evasion, indicating that it is a recommendable step in NHS programs in the NICU. The incidence of hearing loss was 2.9%, considering sensorineural hearing loss (0.91%), conductive (1.83%) and auditory neuropathy spectrum (0.19%).

show abstract